Literature DB >> 15166615

DNA repair pathways in drug resistance in melanoma.

Penny A Bradbury1, Mark R Middleton.   

Abstract

Metastatic melanoma has a poor prognosis due to resistance to multiple chemotherapy regimens. The mainstay of treatment remains dacarbazine, with cisplatin being a commonly used alternative. Melanoma displays marked resistance to the DNA-damaging effects of these drugs. Intrinsic and acquired resistance involves multiple cellular pathways of damage recognition, repair and apoptosis. Increased understanding of these pathways is identifying novel targets that it is hoped will make inroads into the treatment of this lethal disease.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15166615     DOI： 10.1097/01.cad.0000127665.74096.93

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN： 0959-4973            Impact factor:   2.248


  13 in total

1.  The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization.

Authors:  Harriet M Kluger; Mary M McCarthy; Ayesha B Alvero; Mario Sznol; Stephan Ariyan; Robert L Camp; David L Rimm; Gil Mor
Journal:  J Transl Med       Date:  2007-01-26       Impact factor: 5.531

2.  RhoJ regulates melanoma chemoresistance by suppressing pathways that sense DNA damage.

Authors:  Hsiang Ho; Jayavani Aruri; Rubina Kapadia; Hootan Mehr; Michael A White; Anand K Ganesan
Journal:  Cancer Res       Date:  2012-09-12       Impact factor: 12.701

3.  Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10).

Authors:  Tong Shen; Ye-Hong Kuang; Charles R Ashby; Yu Lei; Angel Chen; Ying Zhou; Xiang Chen; Amit K Tiwari; Elizabeth Hopper-Borge; Jiangyong Ouyang; Zhe-Sheng Chen
Journal:  PLoS One       Date:  2009-10-20       Impact factor: 3.240

4.  p-Glycoprotein ABCB5 and YB-1 expression plays a role in increased heterogeneity of breast cancer cells: correlations with cell fusion and doxorubicin resistance.

Authors:  Ji Yeon Yang; Seon-Ah Ha; Yun-Sik Yang; Jin Woo Kim
Journal:  BMC Cancer       Date:  2010-07-22       Impact factor: 4.430

Review 5.  Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations.

Authors:  Rajasekharan Somasundaram; Jessie Villanueva; Meenhard Herlyn
Journal:  Adv Pharmacol       Date:  2012

Review 6.  Nanopreparations to overcome multidrug resistance in cancer.

Authors:  Niravkumar R Patel; Bhushan S Pattni; Abraham H Abouzeid; Vladimir P Torchilin
Journal:  Adv Drug Deliv Rev       Date:  2013-08-23       Impact factor: 15.470

7.  Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10).

Authors:  Wen Deng; Chun-Ling Dai; Jun-Jiang Chen; Rishil J Kathawala; Yue-Li Sun; Hai-Fan Chen; Li-Wu Fu; Zhe-Sheng Chen
Journal:  Oncol Rep       Date:  2013-03-22       Impact factor: 3.906

Review 8.  The role of altered nucleotide excision repair and UVB-induced DNA damage in melanomagenesis.

Authors:  Timothy Budden; Nikola A Bowden
Journal:  Int J Mol Sci       Date:  2013-01-09       Impact factor: 5.923

9.  Functional classification of cellular proteome profiles support the identification of drug resistance signatures in melanoma cells.

Authors:  Verena Paulitschke; Verena Haudek-Prinz; Johannes Griss; Walter Berger; Thomas Mohr; Hubert Pehamberger; Rainer Kunstfeld; Christopher Gerner
Journal:  J Proteome Res       Date:  2013-06-19       Impact factor: 4.466

10.  Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.

Authors:  Rishil J Kathawala; Jun-Jiang Chen; Yun-Kai Zhang; Yi-Jun Wang; Atish Patel; De-Shen Wang; Tanaji T Talele; Charles R Ashby; Zhe-Sheng Chen
Journal:  Int J Oncol       Date:  2014-03-13       Impact factor: 5.650
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.